secwatch.observer — SEC 8-K summary
======================================

Issuer:     OSR Holdings, Inc. (OSRH)
CIK:        0001840425
Form:       8-K
Filed at:   2026-01-14T23:59:59+00:00
Accession:  0001213900-26-004199
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

OSR Holdings subsidiary Vaximm gets binding term sheet for VXM01 license: $30M upfront, $815M milestones
--------------------------------------------------------------------------------

- Vaximm, OSR Holdings' subsidiary, enters binding term sheet with BCM Europe for global exclusive license of VXM01.
- Upfront payment of $30M (50% cash, 50% digital assets) and up to $815M in clinical, regulatory, and commercial milestones.
- Definitive agreement targeted by end of May 2026, subject to fairness opinion, board review, and final documentation.
- BCM Europe, the largest OSRH shareholder, will establish a fund (BCM Decentralized Science Investors I) as licensee.
- VXM01 is an oral T-cell vaccination platform targeting VEGFR-2; has shown clinical activity and safety in multiple cancers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840425/000121390026004199/0001213900-26-004199-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840425/000121390026004199/ea0272738-8k_osrhold.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-004199

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer